Decision Letter: Request for 2018 Renewal of Gavi support for Inactivated Polio Vaccine

Your Excellency,

I am writing in relation to Azerbaijan’s request for renewal of the New Vaccine Support (NVS) for Inactivated Polio Vaccine that was reviewed by the Gavi Secretariat on 25 October 2017.

Following the recommendations made by Gavi Secretariat review, I am pleased to inform you that Gavi has approved Azerbaijan’s request to renew Gavi support for Inactivated Polio Vaccine for 2018, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Azerbaijan Support for Inactivated Polio Vaccine (IPV)
Appendix B: Azerbaijan Support for Injection Safety Devices
Appendix C: Description of approved Gavi support to Azerbaijan

Please do not hesitate to contact colleague Ms Jamila Sherova, Senior Country Manager for Azerbaijan, at jsherova@gavi.org if you have any questions or concerns.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division
# Appendix A

## Decision Letter

### Azerbaijan - Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Azerbaijan
2. **Grant number(s):** 1518-AZE-25d-X / 15-AZE-08h-Y
3. **Date of Decision Letter:** 13/12/2017
4. **Date of the Partnership Framework Agreement:** N/A
5. **Programme title:** New Vaccine Support, IPV routine
6. **Vaccine type:** Inactivated Polio Vaccine (IPV)
7. **Requested product presentation and formulation of vaccine**: Inactivated Polio Vaccine, 1 dose per vial, LIQUID
8. **Programme duration**: 2015 - 2018
9. **Indicative Programme Budget:** (subject to the terms of the Partnership Framework Agreement, if applicable)
   
   Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th>2015-2017</th>
<th>2018</th>
<th>Total³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Programme (US$)</td>
<td>1,219,284</td>
<td>578,500</td>
<td>1,797,784</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant / Product switch grant:** US$28,327 net amount disbursed on 5 March 2015.

11. **Indicative Annual Amounts:** )³

<table>
<thead>
<tr>
<th>Number of vaccines to be purchased with Gavi funds</th>
<th>2015-2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV Routine Programme (doses)</td>
<td></td>
<td>197,000</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>1,219,284</td>
<td>578,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF.

13. **Self-procurement:** Not applicable.

14. **Co-financing obligations:** Not applicable

   Gavi’s usual co-financing requirements do not apply to IPV. However, Azerbaijan is encouraged to contribute to vaccine and/or supply costs for IPV.

15. **Operational support for catch-up campaigns:** Not applicable.

16. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>15 May</td>
</tr>
</tbody>
</table>

---

1. Please refer to section 18 for additional information on IPV presentation.
2. This is the entire duration of the Programme.
3. This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
4. This is the amount that Gavi has approved.
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

<table>
<thead>
<tr>
<th>17. Financial clarifications:</th>
<th>Not applicable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>18. Other conditions:</td>
<td>Not applicable.</td>
</tr>
</tbody>
</table>

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Azerbaijan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Azerbaijan.

Signed by
On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country**: Azerbaijan
2. **Grant number**: 17-AZE-32a-X; 18-AZE-32a-X
3. **Date of Decision Letter**: 13/12/2017
4. **Date of the Partnership Framework Agreement**: 
5. **Programme title**: Injection safety devices
6. **Programme duration**: 2017-2018
7. **Programme Budget (indicative)**: (subject to the terms of the partnership framework agreement, if applicable)
   
   | Programme Budget (US$) | 2017 | 2018 | Total
   |-------------------------|------|------|------
   |                         | 16,000 | 9,500 | 25,500 |

8. **Indicative Annual Amounts**: (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>TOTAL injection safety devices to be purchased with Gavi funds in each year</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AD syringes</td>
<td>208,500</td>
<td></td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>2,300</td>
<td></td>
</tr>
<tr>
<td><strong>Annual Amounts for injection safety devices for all Gavi vaccines (US$)</strong></td>
<td>16,000</td>
<td>9,500</td>
</tr>
</tbody>
</table>

9. **Procurement agency**: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

10. **Self-procurement**: Not applicable.

11. **Co-financing obligations**: Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by
On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017

---

6 This does not include vaccines.
7 This is the entire duration of the Programme.
8 This is the total amount endorsed by Gavi for the entire duration of the Programme.
9 This is the amount that Gavi has approved.
Appendix C

Description of Gavi support to «Azerbaijan» (the “Country”)

New Vaccines Support (NVS)

Gavi, The Vaccine Alliance has approved the Country’s request for supply of vaccine doses and related injection safety material which are estimated to be required for the immunization programme as set out in Appendix A, B and C. Financing provided by Gavi for vaccines will be in accordance with:

- The Gavi Guidelines governing Country’s proposal application; and
- The final proposal as approved by the Independent Review Committee (IRC), including any subsequent clarifications.

The vaccines provided will be used as the country has proposed. The principles of the WHO-UNICEF-UNFPA joint statement on safety of injections (WHO/V&B/99.25) shall apply to all immunisation provided with these vaccines.

Any required taxes, customs, toll or other duties imposed on the importation of vaccines and related supplies cannot be paid for using Gavi funds.

The Country shall be solely responsible for any liability that may arise in connection with: (i) the implementation of any programmes in the Country; and (ii) the use or distribution of vaccines and related supplies after title to such supplies has passed to the Country. Gavi shall not be responsible for providing any additional funding to replace any vaccines and related supplies that are, or became, defective or disqualified for whatever reason.

Country Co-financing

In accordance with the Gavi Co-financing Policy, the Country has agreed to make the required contribution to co-financing vaccine doses as indicated in the Decision Letters. Item number 14 of Appendix A, B and C summarises the budget and the quantity of supply that will be procured with country’s funds in the corresponding timeframe. The total co-financing amount indicates costs for the vaccines, related injection safety devices (only applicable to intermediate and graduating countries) and freight.

Countries may select to co-finance through UNICEF Supply Division or self-procure their co-financing requirement following their own procedures, except for the Pneumococcal vaccine that needs to be procured through UNICEF.

If the purchase of the co-financed supply is carried out through UNICEF, the payment is to be made to UNICEF as agreed in the Procurement Services Memorandum of Understanding between UNICEF and the country, and not to Gavi. Please keep in contact with UNICEF to understand the availability of the relevant vaccines and to prepare the schedule of deliveries.

The total co-financing amount expressed in item number 14 of Appendix A, B and C does not contain costs and fees of the relevant Procurement Agency, such as contingency buffer and handling fees.

Information on these extra costs and fees will be provided by the relevant Procurement Agency as part of the cost estimate to be requested by the country. UNICEF will share information with Gavi on the status of purchase of the co-financed supply. In accordance with the Gavi Co-financing Policy (http://www.gavi.org/about/governance/programme-policies/co-financing/), the co-financing contribution is payable annually to UNICEF.
If the purchase of the co-financed supply is carried out by the Government, following its own procurement procedures and not procuring from UNICEF Supply Division or PAHO’s Revolving Fund, the Government must submit to Gavi satisfactory evidence that it has purchased its co-financed portion of the vaccines and related supplies, including by submitting purchase orders, invoices, and receipts to Gavi. Gavi encourages that countries self-procuring co-financed products (i.e. auto-disable syringes and syringe and needle disposal boxes) ensure that products appear on the applicable WHO list of pre-qualified products or, for syringe and needle disposal boxes, that they have obtained a certificate of quality issued by a relevant national authority.

**Gavi support will only be provided if the Country complies with the following requirements:**

**Transparency and Accountability Policy (TAP):** Compliance with any TAP requirements pursuant to the Gavi TAP Policy and the requirements under any Aide Memoire concluded between Gavi and the country.

**Financial Statements & External Audits:** Compliance with the Gavi requirements relating to financial statements and external audits.

**Grant Terms and Conditions:** Compliance with Gavi’s standard grant terms and conditions (attached in Appendix D).

**Country Co-financing:** Gavi must receive proof of country co-payment from the Country such as invoices or shipment receipts if neither UNICEF is the procurement agent for country co-financed vaccine for the prior calendar year.

**Monitoring and Reporting:** Country’s use of financial support for the introduction of new vaccinations with the vaccines specified in Appendix A and B is subject to strict performance monitoring. Gavi uses country systems for monitoring and auditing performance and other data sources including WHO/UNICEF immunisation coverage estimates. As part of this process, National Authorities will be requested to monitor and report on the numbers of children immunized and on co-financing of the vaccine. Country will report on the achievements and request support for the following year on the Gavi country portal. Further information and training on the portal will be provided by March 2016. The portal must contain information on the number of children reported to have been vaccinated with DTP3 and 3 doses of pentavalent vaccine by age 12 months, based on district monthly reports reviewed by the Immunisation Coordination Committee (ICC), and as reported to WHO and UNICEF in the annual Joint Reporting Form (JRF). The portal will also contain information on country’s compliance with the co-financing arrangements outlined in this letter. The NVS request for support for the following year, endorsed by the ICC, should be sent to the Gavi Secretariat no later than 15 May every year. Continued funding beyond what is being approved in this letter is conditional upon a fully up to date country portal and availability of funds.